KDR and renal cell adenocarcinoma: In the last two decades, the treatment paradigm of RCC has evolved from immune cytokine-based approaches to targeted therapies consisting of TKI against VEGF-R (and other key molecules in angiogenic pathways) and inhibitors of mTOR [13].